Projects
Exploring the potential and underlying mechanisms of therapeutic activation of p53 in combination with immunotherapy to stimulate an innate immune response against non-small cell lung cancer. University of Antwerp
Combining immune stimulation with inhibition of immune suppression: towards a novel combination immunotherapy for pancreatic cancer. University of Antwerp
Exploring the potential and underlying mechanisms of therapeutic activation of p53 in combination with immunotherapy to stimulate an innate immune response against non-small cell lung cancer. University of Antwerp
Exploring the potential and underlying mechanisms of therapeutic activation of p53 in combination with immunotherapy to stimulate an innate immune response against non-small cell lung cancer. University of Antwerp
Epigenetic-targeted treatment in multipel myeloma: Identification of new combination strategies focusing on DNA repair and immunotherapy. Vrije Universiteit Brussel
Further development of mRNA Galsomes as nanovaccines for cancer immunotherapy: combination with checkpoint inhibition and translation to the clinic. Ghent University
We recently developed Galsomes, nano-sized particles that trigger a broad antitumor immune response after intravenous delivery. Upon infusion, these nanovaccines specifically target immune cells to which they simultaneously deliver genetic material (mRNA) encoding tumor antigens as well as glycolipids. As a result, as they manage to engage multiple immune effector cells, including Natural Killer T (NKT) cells and cytotoxic T cells (CTLs) to ...
Combining targeted radionuclide therapy and cancer immunotherapy to advance precision medicine through innovation. Vrije Universiteit Brussel
Triple Negative Breast Cancer, Immunotherapy, Tumor microenvironment, Patient selection, Cancer Associated Fibroblasts, Preclinical Models Ghent University
Triple
-negative breast cancer (TNBC) represents 15–20% of all breast cancers (BC) and has the worst outcome of all BC subtypes. Although anti-PD-L1 immune checkpoint blockade (ICB) combined with chemotherapy can improve the outcome only for some patients, clinical benefits remain modest and restricted to a subset of patients. Consequently, there is an important need to define biomarkers that more effectively identify patients who ...
Dual epigenetic targeting and immunotherapy to fight against cancer Vrije Universiteit Brussel
Recent evidence further suggests that these drugs have immunomodulatory properties and synergize with immunotherapy, representing another major breakthrough in cancer therapy. We ...